Travoprost
- Atc Codes:S01EE04
- CAS Codes:157283-68-6
- PHARMGKB ID:157283-68-6
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Austria: Travatan; Belgium: Travatan; Bulgaria: Travatan; Cyprus: Travatan; Czech Republic: Travatan; Denmark: Travatan; Estonia: Travatan; Finland: Travatan; France: Travatan; Germany: Travatan; Greece: Travatan; Hungary: Travatan; Ireland: Travatan; Italy: Travatan; Latvia: Travatan; Lithuania: Travatan; Luxembourg: Travatan; Malta: Travatan; Netherlands: Travatan; Poland: Travatan; Portugal: Travatan; Romania: Travatan; Slovakia: Travatan; Slovenia: Travatan; Spain: Travatan; Sweden: Travatan; UK: Travatan.
North America
Canada: Travatan; USA: Travatan.
Latin America
Argentina: Arvo, Glaucoprost, Glaunot, Travatan; Brazil: Travatan; Mexico: Travatan.
Asia
Japan: Travatanz.
Drug combinations
Travoprost and Timolol
Chemistry
Travoprost: C~26~H~35~F~3~O~6~. Mw: 500.55. (1) [1R-[1α(Z),2β(1E,3R*),3α,5α]]-7-[3,5-Dihydroxy-2-[3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-butenyl]cyclopentyl]-5-heptenoic acid, 1-methylethyl ester; (2)(Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-isopropyl-tolyl)oxy]-1-butenyl]cyclopentyl]-5-heptenoate. CAS-157283-68-6 (1998).
Pharmacologic Category
Antiglaucoma Agents; Prostaglandin Analogs. (ATC-Code: S01EE04).
Mechanism of action
Lowers intraocular pressure by increasing trabecular meshwork and outflow.
Therapeutic use
Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are intolerant of other IOP-lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another IOP-lowering medication.
Pregnancy and lactiation implications
Teratogenic effects observed in animal studies following systemic administration. Contact with contents of vial should be avoided in women who are pregnant or attempting to become pregnant. Excretion in breast milk unknown (use caution).
Unlabeled use
Contraindications
Hypersensitivity to travoprost or any component of the formulation.
Warnings and precautions
Inadvertent contamination of multiple-dose ophthalmic solutions caused bacterial keratitis. May permanently change/increase brown pigmentation of iris, eyelid skin, and eyelashes. In addition, may increase length and/or number of eyelashes (may vary between eyes). Use with caution in intraocular inflammation, aphakic patients, pseudophakic patients with torn posterior lens capsule, or risk factors for macular edema. Safety and efficacy not determined for use in angle-closure, inflammatory, or neovascular glaucoma. Contains benzalkonium chloride, which may be adsorbed by contact lenses.